Evidence map›Paper›PMID 28612278›Full record

Trial reportInternational journal of hematology2017

Efficacy of prophylactic irradiation to the contralateral testis for patients with advanced-stage primary testicular lymphoma: an analysis of outcomes at a single institution.

Ryouji Tokiya, Eisaku Yoden, Kei Konishi, Nobuhiko Kamitani, Junichi Hiratsuka, Risa Koresawa, Tadashi Hirose, Fuminori Sano, Hirotoshi Tokunaga, Toshinori Kondo and 2 more

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in International journal of hematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. PD-L1Haematologica · 2018
    Trial
  2. Article
  3. Article
  4. The Mutation ofJournal of inflammation research · 2022
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Ryouji TokiyaDepartment of Radiation Oncology, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192, Japan. tokiya@med.kawasaki-m.ac.jp.
Eisaku YodenDepartment of Radiation Oncology, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192, Japan.
Kei KonishiDepartment of Radiation Oncology, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192, Japan.
Nobuhiko KamitaniDepartment of Radiation Oncology, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192, Japan.
Junichi HiratsukaDepartment of Radiation Oncology, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192, Japan.
Risa KoresawaDivision of Hematology, Department of Medicine, Kawasaki Medical School, Kurashiki, Japan.
Tadashi HiroseDivision of Hematology, Department of Medicine, Kawasaki Medical School, Kurashiki, Japan.
Fuminori SanoDivision of Hematology, Department of Medicine, Kawasaki Medical School, Kurashiki, Japan.
Hirotoshi TokunagaDivision of Hematology, Department of Medicine, Kawasaki Medical School, Kurashiki, Japan.
Toshinori KondoDivision of Hematology, Department of Medicine, Kawasaki Medical School, Kurashiki, Japan.
Hideho WadaDivision of Hematology, Department of Medicine, Kawasaki Medical School, Kurashiki, Japan.
Takashi SugiharaDivision of Hematology, Department of Medicine, Kawasaki Medical School, Kurashiki, Japan.
Kawasaki Medical School · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrimary testicular lymphoma (PTL) is a rare, extranodal lymphoma that often relapses in the contralateral testis. We evaluated outcomes in patients with any stage of PTL who had received CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) with rituximab chemotherapy and prophylactic radiotherapy to the contralateral testis.

methodsWe retrospectively identified 15 patients (median age 66 years; range 39-81) diagnosed with diffuse large B-cell PTL in the period 2000-2014. Characteristics and outcomes of these cases were evaluated.

resultsAll patients received initial orchiectomy followed by CHOP with or without rituximab. Thirteen patients received prophylactic irradiation to the contralateral testis. During follow-up (median 67 months; range 8-190), one patient died of PTL, three died of other disease, and nine were free from relapse. For stage I-II disease, 5-year progression-free and overall survival rates were 80 and 100%, respectively. For stage III-IV PTL, 5-year progression-free and overall survival rates were 50 and 72%, respectively. Notably, no patient developed contralateral testicular involvement after prophylactic irradiation.

conclusionsThe observed outcomes suggest that the combination of (i) CHOP plus rituximab and (ii) radiotherapy for local recurrence prophylaxis is promising for both stage I-II and stage III-IV PTL.

Indexed as

TestisAdultAgedAged, 80 and overAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDisease-Free SurvivalDoxorubicinFollow-Up StudiesHumansLymphomaMaleMiddle AgedPrednisoneRadiotherapyAntibodies, Monoclonal, Murine-DerivedCyclophosphamideDoxorubicinPrednisoneR-CHOP protocolRituximabVincristineChemotherapyLymphomaRadiotherapyRituximabTestis

Identifiers

PMID28612278
OpenAlexW2626621473

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.